Literature DB >> 21263433

Thyroid cancer in 2010: a roadmap for targeted therapies.

Francesca Carlomagno1, Massimo Santoro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21263433     DOI： 10.1038/nrendo.2010.232

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

1.  Thyroid carcinoma.

Authors:  R Michael Tuttle; Douglas W Ball; David Byrd; Raza A Dilawari; Gerard M Doherty; Quan-Yang Duh; Hormoz Ehya; William B Farrar; Robert I Haddad; Fouad Kandeel; Richard T Kloos; Peter Kopp; Dominick M Lamonica; Thom R Loree; William M Lydiatt; Judith C McCaffrey; John A Olson; Lee Parks; John A Ridge; Jatin P Shah; Steven I Sherman; Cord Sturgeon; Steven G Waguespack; Thomas N Wang; Lori J Wirth
Journal:  J Natl Compr Canc Netw       Date:  2010-11       Impact factor: 11.908

2.  Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.

Authors:  Elaine T Lam; Matthew D Ringel; Richard T Kloos; Thomas W Prior; Michael V Knopp; Jiachao Liang; Steffen Sammet; Nathan C Hall; Paul E Wakely; Vasyl V Vasko; Motoyasu Saji; Pamela J Snyder; Lai Wei; Daria Arbogast; Minden Collamore; John J Wright; Jeffrey F Moley; Miguel A Villalona-Calero; Manisha H Shah
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

3.  Role of H2O2 in RET/PTC1 chromosomal rearrangement produced by ionizing radiation in human thyroid cells.

Authors:  Rabii Ameziane-El-Hassani; Myriem Boufraqech; Odile Lagente-Chevallier; Urbain Weyemi; Monique Talbot; Didier Métivier; Françoise Courtin; Jean-Michel Bidart; Mohammed El Mzibri; Martin Schlumberger; Corinne Dupuy
Journal:  Cancer Res       Date:  2010-04-27       Impact factor: 12.701

4.  Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

Authors:  Keith C Bible; Vera J Suman; Julian R Molina; Robert C Smallridge; William J Maples; Michael E Menefee; Joseph Rubin; Kostandinos Sideras; John C Morris; Bryan McIver; Jill K Burton; Kevin P Webster; Carolyn Bieber; Anne M Traynor; Patrick J Flynn; Boon Cher Goh; Hui Tang; Susan Percy Ivy; Charles Erlichman
Journal:  Lancet Oncol       Date:  2010-09-17       Impact factor: 41.316

5.  Tumorigenic and metastatic activity of human thyroid cancer stem cells.

Authors:  Matilde Todaro; Flora Iovino; Vincenzo Eterno; Patrizia Cammareri; Guido Gambara; Virginia Espina; Gaspare Gulotta; Francesco Dieli; Silvia Giordano; Ruggero De Maria; Giorgio Stassi
Journal:  Cancer Res       Date:  2010-10-19       Impact factor: 12.701

6.  Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo.

Authors:  Kelly A Miller; Nicole Yeager; Kristen Baker; Xiao-Hui Liao; Samuel Refetoff; Antonio Di Cristofano
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

7.  Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.

Authors:  Julio C Ricarte-Filho; Mabel Ryder; Dhananjay A Chitale; Michael Rivera; Adriana Heguy; Marc Ladanyi; Manickam Janakiraman; David Solit; Jeffrey A Knauf; R Michael Tuttle; Ronald A Ghossein; James A Fagin
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

8.  Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.

Authors:  Bruce G Robinson; Luis Paz-Ares; Annetta Krebs; James Vasselli; Robert Haddad
Journal:  J Clin Endocrinol Metab       Date:  2010-04-06       Impact factor: 5.958

9.  DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells.

Authors:  M Gandhi; L W Dillon; S Pramanik; Y E Nikiforov; Y-H Wang
Journal:  Oncogene       Date:  2010-01-25       Impact factor: 9.867

10.  Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.

Authors:  Samuel A Wells; Jessica E Gosnell; Robert F Gagel; Jeffrey Moley; David Pfister; Julie A Sosa; Michael Skinner; Annetta Krebs; James Vasselli; Martin Schlumberger
Journal:  J Clin Oncol       Date:  2010-01-11       Impact factor: 44.544
  10 in total
  9 in total

1.  Association between TP53 Arg72Pro polymorphism and thyroid carcinoma risk.

Authors:  Fang Wang; Peng Wang; Bin Wang; Zheng-Ju Fu; Ying Yuan; Sheng-Li Yan; Wen-Juan Zhao; Yan-Gang Wang
Journal:  Tumour Biol       Date:  2013-12-28

2.  Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.

Authors:  Brendan Frett; Francesca Carlomagno; Maria Luisa Moccia; Annalisa Brescia; Giorgia Federico; Valentina De Falco; Brittany Admire; Zhongzhu Chen; Wenqing Qi; Massimo Santoro; Hong-yu Li
Journal:  Angew Chem Int Ed Engl       Date:  2015-06-30       Impact factor: 15.336

3.  RAP1GAP inhibits cytoskeletal remodeling and motility in thyroid cancer cells.

Authors:  Xiaoyun Dong; Waixing Tang; Stephen Stopenski; Marcia S Brose; Christopher Korch; Judy L Meinkoth
Journal:  Endocr Relat Cancer       Date:  2012-07-22       Impact factor: 5.678

Review 4.  Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF.

Authors:  Z A Antonello; C Nucera
Journal:  Oncogene       Date:  2013-12-23       Impact factor: 9.867

5.  Thyroid cancer cell lines: Critical models to study thyroid cancer biology and new therapeutic targets.

Authors:  Rebecca E Schweppe
Journal:  Front Endocrinol (Lausanne)       Date:  2012-06-19       Impact factor: 5.555

6.  Multiple anti-tumor effects of Reparixin on thyroid cancer.

Authors:  Federica Liotti; Maria De Pizzol; Marcello Allegretti; Nella Prevete; Rosa Marina Melillo
Journal:  Oncotarget       Date:  2017-05-30

7.  miR-19a Is Involved In Progression And Malignancy Of Anaplastic Thyroid Cancer Cells.

Authors:  Giovanna Calabrese; Anna Dolcimascolo; Giuseppe Caruso; Stefano Forte
Journal:  Onco Targets Ther       Date:  2019-11-13       Impact factor: 4.147

Review 8.  Significant associations between X-ray repair cross-complementing group 3 genetic polymorphisms and thyroid cancer risk.

Authors:  Xiao-Long Yu; Hu Liu; Bin Wang; Zheng-Ju Fu; Ying Yuan; Sheng-Li Yan; Wen-Juan Zhao; Yan-Gang Wang; Jianming Cai
Journal:  Tumour Biol       Date:  2013-11-26

9.  Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy.

Authors:  Shu-Fu Lin; Yu-Yao Huang; Jen-Der Lin; Ting-Chao Chou; Chuen Hsueh; Richard J Wong
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.